CNPR Regulatory Compliance & Ethical Standards 4 — Questions and Answers
Question 1: The FDA's regulations on pharmaceutical advertising distinguish between 'reminder ads' and 'full product ads' primarily in that reminder ads:
- May include efficacy claims but not risk information
- Name the product and its drug class but do not make efficacy or risk claims (Correct answer)
- Are limited to over-the-counter products only
- Require prior FDA approval before publication
Correct answer: Name the product and its drug class but do not make efficacy or risk claims
Reminder ads are exempt from the full brief summary requirement because they only state the product name and do not include any claims about the drug's use or benefits.
Question 2: Anti-kickback statute violations in pharmaceutical sales typically involve providing something of value to a healthcare provider with the intent to:
- Educate them about new drug mechanisms
- Induce or reward referrals or prescriptions paid for by federal healthcare programs (Correct answer)
- Support legitimate CME conferences with no prescribing incentives
- Distribute FDA-mandated patient safety literature
Correct answer: Induce or reward referrals or prescriptions paid for by federal healthcare programs
The Anti-Kickback Statute (AKS) prohibits giving, offering, or receiving anything of value intended to generate business reimbursable by federal healthcare programs.
Question 3: When a pharmaceutical company conducts a speaker program for physicians, which of the following activities is prohibited under the PhRMA Code?
- Using FDA-approved slide kits prepared by the company
- Serving a modest meal at the event venue
- Holding the event at a resort or entertainment venue (Correct answer)
- Allowing physicians to earn CME credit for attending
Correct answer: Holding the event at a resort or entertainment venue
PhRMA guidelines require that speaker programs be held in venues conducive to informational exchange, excluding resorts, sporting events, or entertainment venues.
Question 4: Under FDA regulations, a pharmaceutical representative's verbal statements during a sales call are held to the same standard as:
- Informal conversation not subject to regulatory review
- Written promotional materials requiring fair balance and truthfulness (Correct answer)
- Internal communications protected from FDA oversight
- Investigational communications exempt from FDCA labeling rules
Correct answer: Written promotional materials requiring fair balance and truthfulness
The FDA considers all promotional communications — verbal or written — to be subject to the same truthfulness, fair balance, and non-misleading standards.
Question 5: Which of the following best describes the 'learned intermediary doctrine' as it applies to pharmaceutical representatives?
- Reps may rely on physicians to read all package inserts independently without being informed of key risks
- Manufacturers discharge their duty to warn by providing adequate information to prescribing physicians rather than directly to patients (Correct answer)
- Only pharmacists are legally required to communicate drug risks to patients
- Reps must obtain patient consent before discussing medications with physicians
Correct answer: Manufacturers discharge their duty to warn by providing adequate information to prescribing physicians rather than directly to patients
The learned intermediary doctrine holds that adequate warnings to the prescribing physician satisfy the manufacturer's duty to warn, since the physician acts as the expert intermediary.
Question 6: A pharmaceutical company's compliance program is considered effective under OIG guidance if it includes all of the following EXCEPT:
- Written policies and procedures
- Regular compliance training for employees
- A confidential hotline for reporting misconduct
- Guaranteed immunity from prosecution for all violations (Correct answer)
Correct answer: Guaranteed immunity from prosecution for all violations
Effective compliance programs include policies, training, auditing, and reporting mechanisms, but having a program does not grant immunity from prosecution.
Question 7: A pharmaceutical representative who suspects a colleague is falsifying sample accountability records should first:
- Confront the colleague directly and demand they stop
- Report the concern through the company's compliance hotline or to a compliance officer (Correct answer)
- Ignore it since it does not affect their own territory
- Notify the FDA directly without informing the company
Correct answer: Report the concern through the company's compliance hotline or to a compliance officer
Internal compliance reporting channels are the appropriate first step; most companies have confidential hotlines specifically for reporting potential violations.
CNPR Regulatory Compliance & Ethical Standards 4
The FDA's regulations on pharmaceutical advertising distinguish between 'reminder ads' and 'full product ads' primarily in that reminder ads: